Late Stage Chronic Kidney Disease Therapeutics Market

Future Market Insights

Key Insight

The late stage chronic kidney disease therapeutics market is projected to grow from USD 9.1 billion in 2025 to USD 27.2 billion by 2035, at a CAGR of 11.6%. Calcimimetics will dominate with a 34.7% market share, while late stage chronic kidney disease induced hyperphosphatemia will lead the indication segment with a 48.2% share.

July 22, 2025

Anurag Sharma

250 Pages

Cite this Report

Late Stage Chronic Kidney Disease Therapeutics Market

https://www.futuremarketinsights.com/reports/late-stage-chronic-kidney-disease-therapeutics-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Galenica Group
OPKO Pharmaceuticals Medtronic Plc

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Late Stage Chronic Kidney Disease Therapeutics Market

Key Players

Similar Industry Reports